Using data from Truveta, an EMR-based platform with patient records from 31+ US health systems as of December 2023, we examined the prevalence and incidence in 2023 of ventricular arrhythmias and cardiac arrhythmias. Patient groups included epilepsy patients receiving any one of 27 ASMs, epilepsy patients not receiving ASMs, and non-epilepsy patients with a record of any other condition. We also examined the prevalence and incidence of arrhythmias in each monotherapy ASM group. Of the 27 ASMs, 13 had enough relevant data to be included in the monotherapy groups.

Of the three patient groups (total N=32,063,470), the prevalence of all-type cardiac arrhythmias was 23.2% among treated epilepsy patients (n=264,935), 17.6% among untreated epilepsy patients (n=96,028), and 9.8% among non-epilepsy patients (n=31,702,507). The prevalence of ventricular arrhythmias was 2.9%, 1.8%, and 1.3% among treated epilepsy patients, untreated epilepsy patients, and non-epilepsy patients, respectively. The incidence of new arrhythmias was 1.8%, 1.2%, and 0.7% among treated epilepsy patients, untreated epilepsy patients, and non-epilepsy patients, respectively. There was variability in the prevalence and incidence of arrhythmias, independent of the patient group size, when various ASMs were taken as monotherapy.